(0.33%) 5 116.58 points
(0.32%) 38 361 points
(0.38%) 15 988 points
(-0.99%) $83.02
(5.36%) $2.03
(0.30%) $2 354.30
(0.40%) $27.65
(4.14%) $960.25
(-0.27%) $0.932
(-0.45%) $10.98
(-0.58%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics...
Stats | |
---|---|
本日の出来高 | 93 338.00 |
平均出来高 | 922 903 |
時価総額 | 45.45M |
EPS | $0 ( 2024-03-11 ) |
次の収益日 | ( $-0.0900 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.750 |
ATR14 | $0.00300 (0.85%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | General Resonance Llc | Sell | 7 500 | Common Stock |
2024-04-09 | General Resonance Llc | Sell | 7 500 | Common Stock |
2024-04-09 | General Resonance Llc | Sell | 7 500 | Common Stock |
2024-03-11 | Kiernan Matthew | Buy | 29 481 | Stock Options (Right to buy) |
2024-03-11 | Matlin David J | Buy | 57 488 | Stock Options (Right to buy) |
INSIDER POWER |
---|
99.20 |
Last 99 transactions |
Buy: 46 168 962 | Sell: 338 048 |
ボリューム 相関
Clene Inc. 相関
10 最も正の相関 | |
---|---|
ATNF | 0.907 |
CMTL | 0.906 |
ADN | 0.906 |
MAGS | 0.905 |
PROG | 0.904 |
BEEM | 0.901 |
CTMX | 0.901 |
OPINL | 0.901 |
INVZ | 0.898 |
REFR | 0.897 |
10 最も負の相関 | |
---|---|
TIOA | -0.905 |
LFST | -0.896 |
TIOAU | -0.895 |
SWAV | -0.889 |
BRIVU | -0.888 |
LEDS | -0.885 |
VLAT | -0.885 |
JAQC | -0.885 |
CREX | -0.882 |
BRIV | -0.88 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Clene Inc. 相関 - 通貨/商品
Clene Inc. 財務諸表
Annual | 2023 |
収益: | $654 000 |
総利益: | $-1.17M (-179.20 %) |
EPS: | $-0.470 |
FY | 2023 |
収益: | $654 000 |
総利益: | $-1.17M (-179.20 %) |
EPS: | $-0.470 |
FY | 2022 |
収益: | $473 000 |
総利益: | $447 000 (94.50 %) |
EPS: | $-0.230 |
FY | 2021 |
収益: | $723 000 |
総利益: | $434 000 (60.03 %) |
EPS: | $-0.160 |
Financial Reports:
No articles found.
Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。